文献速递免疫规划卫生政策与健康促进

模拟研究评估日本从三价流感疫苗改为四价流感疫苗的长期效果

Simulation studies to assess the long-term effects of Japan's change from trivalent to quadrivalent influenza vaccination.
PubMed 文献 · Vaccine · 2017-12-29

日本于2015年将三价流感疫苗(TIV)替换为四价流感疫苗(QIV),本研究用个体模拟工具4Flu模拟20个季节的流感传播,发现QIV每年可减少548例流感病例、1.62例住院和0.078例死亡每10万人,并节省107.52百万美元(社会视角),支付方视角的ICER为3698美元/年生命挽救。结论认为QIV在日本具有成本效果(支付方视角)甚至节省成本(社会视角)。

要点

  • QIV每年平均减少548例流感病例,相当于使用TIV时病例的4.7%和流感B的11.9%。
  • QIV每年每10万人减少1.62例住院和0.078例死亡。
  • 日本人口中每年获得915.06年生命挽救,社会视角节省107.52百万美元,支付方视角ICER为3698美元/年生命挽救。

核心结论

  • QIV在日本具有成本效果(支付方视角)甚至节省成本(社会视角)。

研究设计与样本

  • 使用个体模拟工具4Flu,基于官方人口数据和日本接触模式,模拟四种流感毒株的季节传播,从2015/16季节开始评估20年。
  • 模型考虑母体保护、免疫增强、新漂移变异以及自然感染和疫苗诱导免疫的不同免疫持续时间。
  • 使用报告的疫苗接种覆盖率,分别模拟TIV或QIV,计算成本和年生命挽救(YOLS),以2015年为基准年按2%贴现。

主要发现

  • QIV每年平均预防548例流感病例(占使用TIV时发生病例的4.7%;占流感B的11.9%),每10万人减少1.62例住院和0.078例死亡。
  • 在日本125.35百万人口中,每年通过QIV获得915.06年生命挽救,社会视角节省107.52百万美元。
  • 支付方视角的ICER为3698美元/年生命挽救。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since 2013/2014, the WHO has been recommending quadrivalent influenza vaccines (QIV) to prevent seasonal influenza. In 2015, Japan replaced trivalent influenza vaccines (TIV) by QIV. We used computer simulations to calculate how this impacted the epidemiology and to assess its cost-effectiveness. METHODS: We simulated the seasonal transmission of the four influenza strains A(H1N1), A(H3N2), B/Yamagata and B/Victoria with the individual-based simulation tool 4Flu, using official demographic data and Japanese contact patterns. The model considered maternal protection, immunity boosting, new drift variants and different immunity durations for naturally acquired and vaccination-derived immunity. Starting with the 2015/16 season, simulations were evaluated for 20 years, using either TIV or QIV with the reported vaccination coverage. Costs and years of life saved (YOLSs) were calculated and discounted at 2%, using 2015 as base year. RESULTS: QIV annually prevents on average 548 influenza cases (4.7% of cases which occur when using TIV; 11.9% of influenza B), 1.62 hospitalizations and 0.078 deaths per 100,000 individuals. In Japan's population of 125.35 million, annually 915.06 YOLYs are gained by QIV and 107.52 million USD are saved (societal perspective) [corrected]. From payer perspective, the ICER is 3698 USD/YOLS. CONCLUSIONS: QIV is cost-effective (payer perspective) or even cost-saving (societal perspective) in Japan.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tsuzuki S, Schwehm M, Eichner M, et al. Simulation studies to assess the long-term effects of Japan's change from trivalent to quadrivalent influenza vaccination. Vaccine. 2017. PMID: 29292176. doi:10.1016/j.vaccine.2017.12.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。